Equities research analysts expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to post earnings per share of ($0.75) for the current quarter, according to Zacks. Four analysts have made estimates for Kala Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.78) and the highest estimate coming in at ($0.73). Kala Pharmaceuticals reported earnings per share of ($0.46) in the same quarter last year, which indicates a negative year over year growth rate of 63%. The company is expected to issue its next quarterly earnings results on Thursday, May 9th.
On average, analysts expect that Kala Pharmaceuticals will report full year earnings of ($2.83) per share for the current fiscal year, with EPS estimates ranging from ($3.17) to ($2.44). For the next financial year, analysts anticipate that the business will report earnings of ($2.06) per share, with EPS estimates ranging from ($2.81) to ($1.37). Zacks’ EPS averages are an average based on a survey of research analysts that cover Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.23).
A number of hedge funds have recently bought and sold shares of KALA. American International Group Inc. raised its stake in Kala Pharmaceuticals by 34.3% during the 4th quarter. American International Group Inc. now owns 10,369 shares of the company’s stock worth $51,000 after buying an additional 2,646 shares during the period. Rhumbline Advisers acquired a new position in Kala Pharmaceuticals during the 4th quarter worth approximately $75,000. Bradley Foster & Sargent Inc. CT acquired a new position in Kala Pharmaceuticals during the 4th quarter worth approximately $115,000. United Services Automobile Association raised its stake in Kala Pharmaceuticals by 33.6% during the 4th quarter. United Services Automobile Association now owns 24,218 shares of the company’s stock worth $118,000 after buying an additional 6,088 shares during the period. Finally, Squarepoint Ops LLC raised its stake in Kala Pharmaceuticals by 12.4% during the 4th quarter. Squarepoint Ops LLC now owns 27,871 shares of the company’s stock worth $136,000 after buying an additional 3,071 shares during the period. 67.20% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:KALA opened at $8.02 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 10.41 and a quick ratio of 10.17. Kala Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $17.53.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Recommended Story: What Are Cryptocurrencies?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.